PT  - JOURNAL ARTICLE
AU  - Banke-Thomas, Aduragbemi
AU  - Makwe, Christian Chigozie
AU  - Balogun, Mobolanle
AU  - Afolabi, Bosede Bukola
AU  - Alex-Nwangwu, Theresa Amaogechukwu
AU  - Ameh, Charles Anawo
TI  - A Cost Analysis of Childbirth for Pregnant Women with COVID-19 in Nigeria’s Epicentre
AID  - 10.1101/2020.09.22.20199265
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.22.20199265
4099  - http://medrxiv.org/content/early/2020/09/23/2020.09.22.20199265.short
4100  - http://medrxiv.org/content/early/2020/09/23/2020.09.22.20199265.full
AB  - The Coronavirus disease 2019 (COVID-19) has been a major disruptor of health systems globally. Its emergence has warranted the need to reorganize maternity services for childbirth. However, it is not known if this comes at an additional cost to women. We conducted a hospital-based cost analysis to estimate the out-of-pocket cost of spontaneous vaginal delivery (SVD) and caesarean delivery (CD). Specifically, we collected facility-based and household costs of all nine pregnant women with COVID-19 who were managed between 1st April and 30th August 2020 at the largest teaching hospital in Lagos, the epicentre of COVID-19 in Nigeria. We compared the mean facility-based costs for the cohort with costs paid by pregnant women pre-COVID-19, identifying major cost drivers. We also estimated what would have been paid without subsidies, testing assumptions with a sensitivity analysis. Findings showed that total utilization cost ranged from US$494 (N190,150) for SVD with mild COVID-19 to US$4,553 (N1,751,165) for emergency CD with severe COVID-19. Though 32-66% of facility-based cost has been subsidized, cost of SVD and CD have doubled and tripled respectively during the pandemic compared to those paid pre-COVID. Out of the facility-based costs paid, cost of personal protective equipment (PPE) was the major cost driver (50%) for SVD and CD. Supplemental oxygen was a major cost driver when women had severe COVID-19 symptoms and required long admission (48%). Excluding treatment costs specifically for COVID-19, mean facility-based costs for SVD and CD are US$228 (N87,750) and US$948 (N364,551) respectively. Our study demonstrates that despite cost exemptions and donations, utilization costs remain prohibitive. Regulation of the PPE and medical oxygen supply chain can help drive down utilization cost and reduce mark-ups being passed to users. The pandemic offers an opportunity to expand advocacy for subscription to health insurance schemes in order to avoid any catastrophic health expenditure.KEY MESSAGESTotal utilization cost ranged from US$494 (N190,150) for spontaneous vaginal delivery with mild COVID-19 to US$4,553 (N1,751,165) for emergency caesarean delivery with severe COVID-19.Cost of personal protective equipment was the major cost driver (50%) for vaginal and elective caesarean deliveries. Medical oxygen was a major cost driver when women had severe COVID-19 symptoms (48%) and required long admission.Though 32-66% of total cost have been subsidized, facility-based cost of vaginal and caesarean deliveries has doubled and tripled respectively during the pandemic compared to those paid pre-COVID.The study findings highlight the urgent need to implement strategies that can help to minimize the rising costs that pregnant women with COVID-19 face in accessing and utilizing critical intra-partum care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this studyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval to conduct the study was obtained from the Health Research and Ethics Committee of the Lagos University Teaching Hospital (LUTHHREC/EREV/0520/24).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are presented in the manuscript.